FindTrial
Sign In

The mechanism of RPL-23 promoting cisplatin resistance in ovarian cancer cells

RPL-23 promotes cisplatin resistance through DNA damage repair in ovarian cancer cells

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100043896
Enrollment
Unknown
Registered
2021-03-04
Start date
2021-04-01
Completion date
Unknown
Last updated
2021-07-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ovarian cancer

Interventions

drug resistance group vs. non resistance group:Nil

Sponsors

The Second Affiliated Hospital of Nanchang University
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: 1. To receive initial comprehensive staging surgery and tumor cell reduction; 2. High grade serous ovarian cancer was diagnosed by postoperative pathology; 3. All patients received platinum-based combined chemotherapy after surgery.

Exclusion criteria

Exclusion criteria: 1. Those who received preoperative chemoradiotherapy and hormone therapy; 2. Complicated with other cancers.

Design outcomes

Primary

MeasureTime frame
ribosomal protein L23;—

Countries

China

Contacts

Public ContactFen Fu

The Third Affiliated Hospital of Nanchang University

fu_fen@163.com+86 13330127680

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026